Document Detail


A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
MedLine Citation:
PMID:  20371346     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Accumulating evidence implicates heterogeneity within cancer cell populations in the response to stressful exposures, including drug treatments. While modeling the acute response to various anticancer agents in drug-sensitive human tumor cell lines, we consistently detected a small subpopulation of reversibly "drug-tolerant" cells. These cells demonstrate >100-fold reduced drug sensitivity and maintain viability via engagement of IGF-1 receptor signaling and an altered chromatin state that requires the histone demethylase RBP2/KDM5A/Jarid1A. This drug-tolerant phenotype is transiently acquired and relinquished at low frequency by individual cells within the population, implicating the dynamic regulation of phenotypic heterogeneity in drug tolerance. The drug-tolerant subpopulation can be selectively ablated by treatment with IGF-1 receptor inhibitors or chromatin-modifying agents, potentially yielding a therapeutic opportunity. Together, these findings suggest that cancer cell populations employ a dynamic survival strategy in which individual cells transiently assume a reversibly drug-tolerant state to protect the population from eradication by potentially lethal exposures.
Authors:
Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Related Documents :
2743306 - Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for t...
6615686 - Some tetracycline drugs suppress mitogen-stimulated lymphocyte growth but others do not.
21609756 - Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.
7444146 - Clinical correlations of drug sensitivity in the human tumor stem cell assay.
15211616 - Qt prolongation in anaesthetized guinea-pigs: an experimental approach for preliminary ...
15616666 - Update on antiobesity drugs.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cell     Volume:  141     ISSN:  1097-4172     ISO Abbreviation:  Cell     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-07     Completed Date:  2010-04-22     Revised Date:  2011-07-27    
Medline Journal Info:
Nlm Unique ID:  0413066     Medline TA:  Cell     Country:  United States    
Other Details:
Languages:  eng     Pagination:  69-80     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA 02129, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Line, Tumor
Chromatin / metabolism,  pathology
DNA Damage
Drug Resistance, Neoplasm*
Histone Deacetylase Inhibitors / pharmacology
Histone Demethylases / metabolism
Humans
Jumonji Domain-Containing Histone Demethylases / antagonists & inhibitors,  genetics,  metabolism
Neoplasms / drug therapy*,  metabolism,  pathology*
Receptor, IGF Type 1 / metabolism
Grant Support
ID/Acronym/Agency:
P20 CA090578/CA/NCI NIH HHS; P50 CA090578-060008/CA/NCI NIH HHS; P50 CA090578-070008/CA/NCI NIH HHS; R01 CA142825-01/CA/NCI NIH HHS; R01CA115830/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Chromatin; 0/Histone Deacetylase Inhibitors; EC 1.14.11.-/Histone Demethylases; EC 1.14.11.-/Jumonji Domain-Containing Histone Demethylases; EC 1.5.-/KDM4A protein, human; EC 2.7.10.1/Receptor, IGF Type 1
Comments/Corrections
Comment In:
Cell. 2010 Apr 2;141(1):18-20   [PMID:  20371339 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Matrix metalloproteinases: regulators of the tumor microenvironment.
Next Document:  Persistent telomere damage induces bypass of mitosis and tetraploidy.